In a move the White House calls historic, President Donald Trump has announced a sweeping deal with pharmaceutical giants Eli Lilly and Novo Nordisk to slash the cost of America’s most expensive weight-loss and diabetes medications.
Under the agreement, the list prices of Ozempic, Wegovy, Zepbound, and related GLP-1 drugs will fall by as much as 75 percent, marking one of the largest negotiated drug-price reductions in U.S. history.
An Historic Price Drop
For years, the cost of GLP-1 medications has hovered between $1,000 and $1,350 per month, putting them out of reach for millions who struggle with obesity, diabetes, or cardiovascular disease.
Through the new program—called TrumpRx—those same treatments will now be available for $350 per month, with even deeper discounts on future oral versions priced at $150 per month once approved by the FDA.
The deal also locks in lower government reimbursement rates.
Under the new framework, the Medicare price for Ozempic, Wegovy, Mounjaro, and Zepbound is $245 per month, with beneficiaries paying a $50 co-pay.
State Medicaid programs will have access to these same prices, and Medicare will cover Wegovy and Zepbound for patients with obesity and related comorbidities for the first time.
What Exactly Is TrumpRx?
TrumpRx is the administration’s new direct-purchase program announced by the White House. It allows Americans to buy select medications at capped, negotiated prices — for GLP-1 drugs, that’s $350 per month for injectables and $150 per month for oral versions if later approved by the FDA — without relying on list prices that can exceed $1,000.
The initiative is built in partnership with participating manufacturers and is intended to bypass insurance markups, providing transparent pricing that mirrors international “Most Favored Nation” standards.
Consumers will also be able to purchase other discounted medicines through the same channel, including Emgality at $299 per pen, Trulicity at $389 per month, and insulin brands NovoLog and Tresiba at $35 per month of supply.
A quote from the TrumpRx.gov website homepage reads:
“For many years, Americans have paid the highest prices anywhere in the world for prescription drugs — much more than other countries for the exact same product. That ends today.”
– President Donald Trump
Beyond Obesity: A Broader Price Reset
Both Eli Lilly and Novo Nordisk have agreed to guarantee Most Favored Nation (MFN) pricing on all new medicines, repatriate increased foreign revenue from existing products, and extend those prices to every state Medicaid program.
In effect, the framework resets how U.S. drug prices are negotiated—tethering domestic prices to international parity.
Economic and Public-Health Implications
The immediate beneficiaries are the tens of millions of adults managing obesity or Type 2 diabetes, but the ripple effects reach much further. Lower list prices could ease national healthcare spending, expand access to preventive care, and reduce long-term risks associated with chronic disease.
Analysts say that if TrumpRx enrollment reaches critical mass, annual savings to Medicare and Medicaid could reach tens of billions of dollars, while private insurers may face pressure to match government pricing.
At the same time, industry observers warn that pharmaceutical companies may need to rebalance R&D budgets and international pricing models as they adapt to mandatory price alignment. Investors are watching closely as markets weigh the consumer benefit against potential pressure on profits.
A Turning Point in the Weight-Loss Revolution
Obesity drugs have become the defining blockbuster of the decade—transforming public conversation around health, self-image, and longevity. But they’ve also highlighted a stark divide in access: effective for those who can afford them, unattainable for many who can’t.
TrumpRx aims to change that equation. By collapsing layers of cost and introducing transparent, capped pricing, it offers a blueprint for how high-demand medications can be democratized without fully socializing the system that delivers them.
Still, the plan’s success will hinge on supply stability, FDA approvals for oral formulations, and insurer integration. If those pieces align, TrumpRx could become a case study in how pricing reform—once thought politically impossible—reshapes both markets and lives.
From The Readovia Lens
For the first time, America’s most expensive lifestyle-health drugs are being treated as essential, not elite.
Whether TrumpRx marks the start of true transparency in drug pricing—or simply a high-profile exception—will depend on how the rest of the pharmaceutical industry responds.
But for millions of Americans battling chronic disease, this moment feels less like politics and more like progress.
